Monte Rosa Therapeutics, Inc. (GLUE)
2025-06-30 | 2025-03-31 | 2024-09-30 | ||
|---|---|---|---|---|
| Collaboration revenue | 23,194 | 84,929 | 9,216 | |
| Research and development | 30,653 | 32,190 | 27,616 | |
| General and administrative | 8,095 | 8,703 | 8,127 | |
| Total operating expenses | 38,748 | 40,893 | 35,743 | |
| (loss) income from operations | -15,554 | 44,036 | -26,527 | |
| Interest income | 3,068 | 3,439 | 2,892 | |
| Gain on disposal of property and equipment | - | 59 | - | |
| Foreign currency exchange gain (loss), net | 1,390 | 173 | -153 | |
| Total other income | 4,458 | 3,671 | 2,739 | |
| Net (loss) income before income taxes | -11,096 | 47,707 | -23,788 | |
| Provision for income taxes | 1,199 | 822 | 71 | |
| Net (loss) income | -12,295 | 46,885 | -23,859 | |
| Unrealized loss on available-for-sale securities | 97 | - | - | |
| Provision for pension benefit obligation | 53 | 48 | 37 | |
| Unrealized gain on available-for-sale securities | - | 21 | -311 | |
| Comprehensive (loss) income | -12,339 | 46,912 | -23,511 | |
| Weighted-average number of common shares used in computing net loss per share-basic | 82,186,768 | 82,148,719 | 82,011,670 | |
| Weighted-average number of common shares used in computing net loss per share-diluted | 82,186,768 | 82,956,423 | 82,011,670 | |